02 · Monthly Pulse
Top signals across four OTC therapeutic segments, framed for consultant use. Monograph reform, Rx-to-OTC pipeline, and competitive brand moves — updated monthly by Brendan Walsh.
Edition 05 · November 2026
November 2026Ultra Violette's Unblock Screen SPF 50 launched August 31, 2026 as the first US sunscreen to use bemotrizinol, sold through Sephora. dsm-firmenich's Parsol Shield ingredient is also reaching other formulators, and a follow-up Ultra Violette product is planned for January 2027.
Consumer search and social signals also inform velocity rating.
FDA's oral phenylephrine removal order, proposed November 2024 with comments closing May 2025 and once expected "sometime in 2026," still has not published. Meanwhile a narrower August 2026 Federal Register amendment recognized phenylephrine bitartrate as safe and effective specifically in effervescent dosage form (alone, or combined with aspirin and chlorpheniramine), removing sinusitis as a permitted indication in that form.
Consumer search and social signals also inform velocity rating.
FDA approved Rextovy, a 4 mg naloxone nasal spray from Amphastar, for OTC sale on June 16, 2026, joining Narcan and RiVive as the third Rx-to-OTC naloxone switch. Competition has already pushed retail prices down, from Narcan's original $44.99 two-pack toward a $19 CalRx generic. Rextovy's OTC price was not yet set as of this edition, and the product was not yet stocked at major chains.
Consumer search and social signals also inform velocity rating.
FDA's OMUFA reauthorization program page confirms the FY2026-2030 user-fee structure is in effect.
Consumer search and social signals also inform velocity rating.
FTC enforcement activity, including a settlement with a telemedicine company over GLP-1-related marketing claims, shows the agency applying the same substantiation standard across telehealth and OTC-adjacent brands, not only dietary supplements.
Consumer search and social signals also inform velocity rating.